[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100534707":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":13,"locations":22,"responsibleParty":50,"collaborators":7,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":54,"sex":60,"minAge":61,"maxAge":7,"enrollmentInfo":62,"targetDuration":7,"studyType":65,"phases":7,"briefSummary":66,"conditions":67,"keywords":69,"overallStatus":39,"whyStopped":7,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Mario Negri Institute for Pharmacological Research","OTHER",null,[9],{"name":10,"affiliation":11,"role":12},"Giuseppe Remuzzi, MD","Istituto Di Ricerche Farmacologiche Mario Negri","STUDY_DIRECTOR",[14,19],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Matias Trillini, MD","CONTACT","+3903545351","matias.trillini@marionegri.it",{"name":20,"role":16,"phone":7,"phoneExt":7,"email":21},"Piero L Ruggenenti, MD","pruggenenti@asst-pg23.it",[23,37],{"facility":24,"status":25,"city":26,"state":27,"zip":28,"country":29,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":7},"ASST HPG23 - Unità di Nefrologia","ACTIVE_NOT_RECRUITING","Bergamo","BG","24127","Italy","IT",{"type":32,"coordinates":33},"Point",[34,35],9.66721,45.69601,{"lat":35,"lon":34},{"facility":38,"status":39,"city":40,"state":27,"zip":41,"country":29,"countryCode":30,"cosmosGeoPoint":42,"geoPoint":46,"contacts":47},"Centro di Ricerche Cliniche per le Malattie Rare \"Aldo e Cele Daccò\"","RECRUITING","Ranica","24020",{"type":32,"coordinates":43},[44,45],9.71335,45.72328,{"lat":45,"lon":44},[48],{"name":15,"role":16,"phone":49,"phoneExt":7,"email":18},"0039 035 45351",{"type":51,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100534707","an-outcome-analysis-of-primary-membranous-nephropathy-100534707",false,"NCT06242327","An Outcome Analysis of Primary Membranous Nephropathy","An Observational, Longitudinal Study to Describe the Outcome, and Outcome Predictors, of Patients With Primary Membranous Nephropathy, and the Nephrotic Syndrome Treated With Rituximab, or Other Monoclonal Antibodies","PROMENADE","Inclusion Criteria:\n\n* Adults (≥18 years old) on the day of signing informed consent.\n* Diagnosis of primary membranous nephropathy\n* Nephrotic syndrome (proteinuria \\>3.5 g\u002F24 hours)\n* Written informed consent to the use of recorded data for research purposes.\n\nExclusion Criteria:\n\n* Legal incapacity or limited legal capacity.\n* Any contraindication to treatment with rituximab or other monoclonal antibody","ALL","18 Years",{"count":63,"type":64},500,"ESTIMATED","OBSERVATIONAL","This is an observational study intended to track the course of the primary membranous nephropathy disease in real-world clinical practice.\n\nThe study will primarily assess the long-term outcomes of patients with primary membranous nephropathy in the context of advances in treatment options.",[68],"Membranous Nephropathy",[70,71],"Primary Membranous Nephropathy","Nephrotic Syndrome","2026-03-19",{"date":74,"type":75},"2026-03-23","ACTUAL",{"date":77,"type":75},"2024-11-29",{"date":79,"type":64},"2054-06",{"name":5,"class":6},2]